Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Leases (2022 - 2025)

NewAmsterdam Pharma's Current Leases history spans 4 years, with the latest figure at $136000.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 44.72% year-over-year to $136000.0; the TTM value through Dec 2025 reached $136000.0, down 44.72%, while the annual FY2025 figure was $136000.0, 44.72% down from the prior year.
  • Current Leases for Q4 2025 was $136000.0 at NewAmsterdam Pharma, down from $181000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $252000.0 in Q1 2025 and bottomed at $43000.0 in Q1 2024.
  • The 4-year median for Current Leases is $203000.0 (2025), against an average of $168025.5.
  • The largest YoY upside for Current Leases was 486.05% in 2025 against a maximum downside of 44.72% in 2025.
  • A 4-year view of Current Leases shows it stood at $63255.3 in 2022, then decreased by 5.15% to $60000.0 in 2023, then surged by 310.0% to $246000.0 in 2024, then crashed by 44.72% to $136000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Current Leases are $136000.0 (Q4 2025), $181000.0 (Q3 2025), and $225000.0 (Q2 2025).